Jonathan Mosley

Sources

Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.

1. [1]

   Jonathan Mosley, M.D., Ph.D. - Faculty Profile - UT Southwestern

   19 source claims · Reviewed Sep 7, 2026

   Show supporting evidence

   Biographical context: His research develops and evaluates polygenic methods for clinical risk prediction and studies relationships among genetic variation, biomarkers, disease, and iatrogenic harm. Additional areas include metabolomics, proteomics, prostate cancer, cardiac disease, and health inequities.

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Biographical context: Jonathan Mosley is a physician-scientist who treats resistant hypertension and studies how complex genetics can inform risk prediction and clinical decisions. His research uses electronic health record-linked DNA biobanks and other large clinical and epidemiological datasets.

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Biographical context: Mosley is an Associate Professor of Internal Medicine with clinical training in internal medicine and clinical pharmacology. His clinical focus is the diagnosis and treatment of resistant hypertension.

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Fellowship: Vanderbilt University Medical Center (Clinical Pharmacology)

   Through 2014

   Education Other Case Western Reserve University (2007), Doctor of Philosophy Pharmacology Medical Education Case Western Reserve University (2009) Residency Vanderbilt University Medical Center (2011), Internal Medicine Fellowship Vanderbilt University Medical Center (2014), Clinical Pharmacology

   Graduate education: Case Western Reserve University (Doctor of Philosophy in Pharmacology)

   Through 2007

   Education Other Case Western Reserve University (2007), Doctor of Philosophy Pharmacology Medical Education Case Western Reserve University (2009) Residency Vanderbilt University Medical Center (2011), Internal Medicine Fellowship Vanderbilt University Medical Center (2014), Clinical Pharmacology

   Graduate education: Johns Hopkins Bloomberg School of Public Health (Master of Science in Chronic Disease Epidemiology)

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Official headshot: Portrait

   <img src="https://profileplus.swmed.edu/facultydata/231577/images/mosley-jonathan-inset.jpg" class="card__image" itemprop="image" alt="Jonathan Mosley, M.D., Ph.D. " style="max-width:200px;" />

   Medical school: Case Western Reserve University (Medical degree)

   Through 2009

   Education Other Case Western Reserve University (2007), Doctor of Philosophy Pharmacology Medical Education Case Western Reserve University (2009) Residency Vanderbilt University Medical Center (2011), Internal Medicine Fellowship Vanderbilt University Medical Center (2014), Clinical Pharmacology

   Official profile: Official profile

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Research interests: Complex human genetics

   Research Interest Complex human genetics Epidemiology Health inequities Risk factors

   Research interests: Epidemiology

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Research interests: Health inequities

   Research Interest Complex human genetics Epidemiology Health inequities Risk factors

   Research interests: Metabolomics

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Research interests: Polygenic methods

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Research interests: Proteomics

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Research interests: Resistant hypertension

   Biography Jonathan D. Mosley, M.D., Ph.D., is a clinically trained physician scientist and associate professor in the Department of Internal Medicine at UT Southwestern Medical Center. He has a Master’s in Science in Chronic Disease Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed an M.D./Ph.D. program at Case Western Reserve University, where his thesis work focused on molecular and mouse models of mammary gland tumorigenesis. Dr. Mosley completed a residency in Internal Medicine at Vanderbilt University Medical Center. His clinical focus is on the diagnosis and treatment of resistant hypertension. He is a Fellow of the American Heart Association and a member of the American Society of Human Genetics. Dr. Mosley’s research focus is on the translation of complex genetics to clinical medicine with the goal of improving health care delivery, reducing unnecessary health care utilization, and improving risk stratification. In particular, he focuses on developing, evaluating and implementing polygenic methods to guide clinical decision-making, to inform clinical risk prediction and to delineate the etiological relationships between diverse human diseases and putative biomarkers. Much of this work leverages large clinical and epidemiological data resources including electronic health records (EHR)-linked to DNA biobanks. One area of interest is how “benign” genetic variation in clinical biomarkers creates vulnerable populations that are predisposed to iatrogenic harms. Other areas of focus include metabolomics, proteomics, prostate cancer, and cardiac disease.

   Research interests: Risk factors

   Research Interest Complex human genetics Epidemiology Health inequities Risk factors

   Residency: Vanderbilt University Medical Center (Internal Medicine)

   Through 2011

   Education Other Case Western Reserve University (2007), Doctor of Philosophy Pharmacology Medical Education Case Western Reserve University (2009) Residency Vanderbilt University Medical Center (2011), Internal Medicine Fellowship Vanderbilt University Medical Center (2014), Clinical Pharmacology

   Resource: Mosley Lab

   <a href="https://labs.utsouthwestern.edu/mosley-lab">Mosley Lab</a>

2. [2]

   UT Southwestern Division of Cardiology faculty directory

   1 source claim · Reviewed Sep 7, 2026

   Show supporting evidence

   Professional role: Associate Professor

   Jonathan Mosley, M.D., Ph.D. Associate Professor Internal Medicine,Eugene McDermott Center for Human Growth and Development Mosley Research Lab